Date	Title
11/19/19	Alkermes Submits New Drug Application to U.S. Food and Drug Administration for ALKS 3831 for Treatment of Schizophrenia and Bipolar I Disorder
11/18/19	Alkermes to Acquire Rodin Therapeutics
11/12/19	Alkermes' Corporate Presentation to be Webcast at Upcoming Healthcare Conferences
11/12/19	Alkermes Announces Receipt of $150 Million Milestone Payment from Biogen Related to FDA Approval of VUMERITY™
11/08/19	Alkermes Announces New Data From ALKS 4230 Clinical Development Program at Society for Immunotherapy of Cancer's (SITC) 34th Annual Meeting
11/04/19	Alkermes to Present Data From ALKS 4230 Clinical Development Program at the Society for Immunotherapy of Cancer's (SITC) 34th Annual Meeting
10/30/19	Biogen and Alkermes Announce FDA Approval of VUMERITY™ (diroximel fumarate) for Multiple Sclerosis
10/23/19	Alkermes Plc Reports Third Quarter 2019 Financial Results and Implementation of Restructuring
10/21/19	Alkermes Announces Clinical Collaboration With Fred Hutchinson Cancer Research Center for Novel Immuno-Oncology Drug Candidate ALKS 4230
10/16/19	Alkermes to Host Conference Call to Discuss Third Quarter 2019 Financial Results
10/07/19	Alkermes Presents New Health Economics and Outcomes Research on Patients With Schizophrenia and Bipolar I Disorder at 2019 Psych Congress
09/26/19	Alkermes to Present at the Cantor Fitzgerald Global Healthcare Conference
09/13/19	Alkermes Announces the Appointment of Richard Gaynor, M.D. and Andy Wilson to its Board of Directors and the Retirement of Director Floyd Bloom, M.D.
07/30/19	Diroximel Fumarate Demonstrated Significantly Improved Gastrointestinal Tolerability Profile Compared to Dimethyl Fumarate in Patients with Multiple Sclerosis
07/29/19	Alkermes Announces Settlement With Amneal Over VIVITROL® Patent Dispute
07/25/19	Alkermes Plc Reports Second Quarter 2019 Financial Results
07/18/19	Alkermes to Host Conference Call to Discuss Second Quarter 2019 Financial Results
07/15/19	Alkermes Expands Planned New Drug Application for ALKS 3831 to Include Treatment of Bipolar I Disorder
07/01/19	Alkermes Demonstrates Commitment to Local Community for 11th Consecutive Year With Largest Volunteer Event in Company History
06/12/19	Alkermes Advances ALKS 4230 into Monotherapy Expansion Phase of ARTISTRY-1 in Patients With Renal Cell Carcinoma or Melanoma
05/22/19	Alkermes to Present New Data From Mental Health Portfolio at the American Society of Clinical Psychopharmacology 2019 Annual Meeting
05/14/19	Alkermes to Present at the UBS Global Healthcare Conference
05/13/19	Alkermes to Showcase Leadership in Schizophrenia With New Data Presentations at Upcoming Scientific Conferences
04/25/19	Alkermes Plc Reports First Quarter 2019 Financial Results
04/24/19	Alkermes Appoints Industry Veteran C. Todd Nichols as Senior Vice President of Sales and Marketing
04/18/19	Alkermes to Host Conference Call to Discuss First Quarter 2019 Financial Results
04/09/19	Alkermes Announces Positive Topline Results From Innovative Study of ARISTADA® and INVEGA SUSTENNA® for the Treatment of Schizophrenia
04/08/19	Alkermes Announces Departure of Jim Robinson
04/03/19	Alkermes Expands Awards Program With Focus on Advancing Research in Schizophrenia
04/01/19	Alkermes to Present New ALKS 3831 Data From ENLIGHTEN-2 and Interim Extension Safety Study Results at 2019 Congress of the Schizophrenia International Research Society
03/21/19	Alkermes Statement on National Academies of Sciences, Engineering, and Medicine Report on Medications for Opioid Use Disorder
03/05/19	Alkermes' Corporate Presentation to be Webcast at the Cowen and Company 39th Annual Health Care Conference
02/26/19	Alkermes Initiates Clinical Study of ALKS 4230 Administered Subcutaneously in Patients With Advanced Solid Tumors
02/25/19	Alkermes and Biogen Announce U.S. Food and Drug Administration Acceptance of Diroximel Fumarate New Drug Application for Multiple Sclerosis
02/20/19	Alkermes to Present at the 8th Annual SVB Leerink Global Healthcare Conference
02/19/19	Alkermes and Clovis Oncology Initiate Research Collaboration to Explore Combination Cancer Therapies
02/14/19	Alkermes Plc Reports Financial Results for the Year Ended Dec. 31, 2018 and Provides Financial Expectations for 2019
02/07/19	Alkermes to Host Conference Call to Discuss Fourth Quarter and Year-End 2018 Financial Results
02/01/19	Alkermes Receives Complete Response Letter From U.S. Food and Drug Administration for ALKS 5461 New Drug Application
01/16/19	Alkermes Announces Recipients of 1st Annual ALKERMES PATHWAYS RESEARCH AWARDS (SM) Program
01/02/19	Alkermes' Corporate Presentation to be Webcast at the 37th Annual J.P. Morgan Healthcare Conference